Read by QxMD icon Read


Taiji Hasegawa, Sakura Murakawa, Ichiro Maruko, Akiko Kogure-Katakura, Tomohiro Iida
AIM: To determine whether there is a significant correlation between the reduction in macular vessel density and the recurrence of macular oedema in eyes with branch retinal vein occlusion (BRVO). METHODS: We reviewed the medical records of 27 eyes with macular oedema associated with BRVO. All eyes had received pro re nata intravitreal ranibizumab (IVR) injection. A reinjection of ranibizumab was performed when the central foveal thickness was ≥300 µm. At 12 months, patients without additional IVR for the last 4 months were placed in the resolved group, otherwise they were placed in the recurrence group...
March 15, 2018: British Journal of Ophthalmology
Dominika Podkowinski, Ana-Maria Philip, Wolf-Dieter Vogl, Jutta Gamper, Hrvoje Bogunovic, Bianca S Gerendas, Bilal Haj Najeeb, Sebastian M Waldstein, Ursula Schmidt-Erfurth
BACKGROUND/AIMS: To characterise neuroretinal atrophy in retinal vein occlusion (RVO). METHODS: We included patients with central/branch RVO (CRVO=196, BRVO=107) who received ranibizumab according to a standardised protocol for 6 months. Retinal atrophy was defined as the presence of an area of retinal thickness (RT) <260 µm outside the foveal centre. Moreover, the thickness of three distinct retinal layer compartments was computed as follows: (1) retinal nerve fibre layer to ganglion cell layer, (2) inner plexiform layer (IPL) to outer nuclear layer (ONL) and (3) inner segment/outer segment junction to retinal pigment epithelium...
March 6, 2018: British Journal of Ophthalmology
Lasse Jørgensen Cehofski, Anders Kruse, Sigriður Olga Magnusdottir, Alexander Nørgård Alsing, Svend Kirkeby, Bent Honoré, Henrik Vorum
A dexamethasone intravitreal implant (OZURDEX) provides an effective treatment of inflammation secondary to branch retinal vein occlusion (BRVO). Retinal proteome changes which mediate the beneficial effects of the implant remain poorly understood. To study retinal proteome changes in BRVO following an intervention with a dexamethasone (DEX) implant this study combined an experimental model of BRVO with proteomic techniques. In six Danish Landrace pigs experimental BRVO was induced in both eyes using argon laser...
March 2, 2018: Experimental Eye Research
Mika Hosogi, Yuki Morizane, Yusuke Shiode, Shinichiro Doi, Fumiaki Kumase, Shuhei Kimura, Mio Hosokawa, Masayuki Hirano, Shinji Toshima, Kosuke Takahashi, Atsushi Fujiwara, Fumio Shiraga
To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than 12 weeks (continued TAE group). Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and predictive factors for inclusion in the TAE to PRN group were analyzed...
February 2018: Acta Medica Okayama
Donghyoun Noh, Gahyung Ryu, Junyeop Lee, Min Sagong
PURPOSE: To evaluate whether early anatomical and visual acuity (VA) responses to intravitreal bevacizumab (IVB) in macular edema secondary to branch retinal vein occlusion (BRVO) are associated with 1-year follow-up outcomes. METHODS: Ninety-nine treatment-naïve patients (99 eyes) with macular edema after BRVO treated with IVB were analyzed retrospectively. All patients received single injection and were followed up with pro re nata regimen for at least 12 months...
January 31, 2018: Ophthalmologica. Journal International D'ophtalmologie
Su Young Moon, Kwan Hyuk Cho, Se Joon Woo, Sung Pyo Park, Yong Kyu Kim
PURPOSE: To compare visual and anatomical outcomes of intravitreal injections of bevacizumab and dexamethasone implant (Ozurdex) treatment for macular edema associated with branch retinal vein occlusion (BRVO). METHODS: We retrospectively reviewed patients who underwent intravitreal bevacizumab administered monthly on a pro re nata (PRN) basis (26 eyes, IVB group) or an initial 700-μg dexamethasone implant followed by a bevacizumab PRN injection (20 eyes, IVD group) for treatment of macular edema associated with BRVO...
January 25, 2018: Korean Journal of Ophthalmology: KJO
Irena Šínová, Jiří Řehák, Jana Nekolová, Naďa Jirasková, Petra Haluzová, Tereza Řeháková, Barbora Babková, Libor Hejsek, Martin Šín
PURPOSE: The aim of this study was to evaluate the relationship between the ischemic index and the oxygen saturation in retinal vessels in patients with retinal vein occlusion. DESIGN: Prospective, cross-sectional study. METHODS: We performed a prospective study. The cohort consisted of 43 eyes of 43patients with retinal vein occlusions (RVO), 23 of whom had central retinal vein occlusions (CRVO) and 20 who had branch retinal vein occlusions (BRVO)...
January 20, 2018: American Journal of Ophthalmology
Christoph Ehlken, Mandy Helms, Daniel Böhringer, Hansjürgen T Agostini, Andreas Stahl
Purpose: Real-life clinical outcomes of patients treated with anti-VEGF drugs for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or macular edema secondary to branch retinal vein occlusion (BRVO) are often inferior to results from randomized clinical trials. This observational cohort study investigates treatment adherence and real-life clinical outcomes within the first year of treatment. Patients and methods: A total of 708 treatment-naïve patients (466 nAMD, 134 DME, and 108 BRVO) were included...
2018: Clinical Ophthalmology
Francesco Pichi, Ahmed Mohammed Elbarky, Tarek Roshdy Elhamaky
PURPOSE: To compare the efficacy of a modified PRN treatment regimen ("treat and monitor") of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. METHODS: Seventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a "treat and monitor" treatment regimen with monthly follow-up for 12 months...
December 22, 2017: International Ophthalmology
Ilkka Laine, Juha-Matti Lindholm, Petteri Ylinen, Raimo Tuuminen
Purpose: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO). Design: A retrospective single-center study. Subjects: A total of 135 eyes of 135 patients with BRVO (n=83) and CRVO (n=52). Methods: Changes in clinical parameters were recorded before treatment and at the first and third month after commencement of IVB (n=121) and DEX (n=14)...
2017: Clinical Ophthalmology
Meiaad Khayat, Noemi Lois, Michael Williams, Alan W Stitt
Purpose: To provide a comprehensive and current review on the available experimental animal models of retinal vein occlusion (RVO) and to identify their strengths and limitations with the purpose of helping researchers to plan preclinical studies on RVO. Methods: A systematic review of the literature on experimental animal models of RVO was undertaken. Medline, SCOPUS, and Web of Science databases were searched. Studies published between January 1, 1965, and March 31, 2017, and that met the inclusion criteria were reviewed...
December 1, 2017: Investigative Ophthalmology & Visual Science
Amun Sachdev, Magdalena Edington, Rupal Morjaria, Victor Chong
PURPOSE: To compare retinal sensitivity and central retinal thickness in patients with focal diabetic macular edema (DME) and edema secondary to branch retinal vein occlusion (BRVO). METHODS: In this consecutive, cross-sectional, observational study, patients with either DME or BRVO underwent measurements for best-corrected visual acuity, microperimetry, and spectral domain optical coherence tomography. Retinal thickness and sensitivity were measured using Optos Spectral optical coherence tomography/scanning laser ophthalmoscopy (Optos plc, Dunfermline, Scotland, United Kingdom)...
November 22, 2017: Retina
Sibylle Winterhalter, Annabelle Eckert, Gerrit-Alexander Vom Brocke, Alice Schneider, Dominika Pohlmann, Daniel Pilger, Antonia M Joussen, Matus Rehak, Ulrike Grittner
PURPOSE: To evaluate the therapeutic outcome for dexamethasone implant (DEX) or intravitreal ranibizumab (IVR) injections over 6 months in patients with macular edema due to branch or central retinal vein occlusion (BRVO, CRVO), in a real-life setting. METHODS: A total of 107 patients with BRVO or CRVO were included into this retrospective single-center observational study. Patients were treated with monotherapy consisting of DEX or three monthly IVR injections following a pro re nata regimen (PRN)...
February 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
P L Lip, P Cikatricis, A Sarmad, E M Damato, R Chavan, A Mitra, S Elsherbiny, Y Yang, B Mushtaq
PurposeVarious combination treatment regimens have been tried to improve the short-term efficacy of intravitreal monotherapy for the treatment of macular oedema (MO) secondary to retinal vein occlusion (RVO). Our study introduces the RandOL protocol (Ranibizumab and Ozurdex with Laser photocoagulation) of initial anti-VEGF therapy, controlling recurrent non-ischaemic MO with an intravitreal steroid and applying laser therapy to non-perfused retina. We describe our 12-month follow-up experience on timing for adjunctive therapy and real-world effectiveness and safety data...
November 3, 2017: Eye
Hiroyuki Iijima
PURPOSE: To study the reduction in light sensitivity in areas where impaired retinal perfusion was established by fluorescein angiogram (FA) in eyes with branch retinal vein occlusion (BRVO) that recovered from retinal edema and hemorrhage. DESIGN: Retrospective observational case series. METHODS: A study of the reduction in light sensitivity demonstrated by total deviation display of the Humphrey perimetry program 30-2 in 43 eyes from 42 patients with BRVO, whose perfusion status was assessed by FA images taken at least 6 months after disease onset...
November 1, 2017: Japanese Journal of Ophthalmology
Thalmon R Campagnoli, Gábor Márk Somfai, Jing Tian, Delia Cabrera DeBuc, William E Smiddy
BACKGROUND AND OBJECTIVES: Several imaging modalities have been developed to characterize ischemia inherent in retinal vascular diseases. This study aims to predict the impact and to better establish the mechanisms of visual deterioration. A high-resolution functional imaging device is used, yielding quantitative data for macular blood flow and capillary network features in healthy eyes and in eyes with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). PATIENTS AND METHODS: This prospective, cross-sectional, comparative case series measured blood flow velocities (BFVs) and noninvasive capillary perfusion maps (nCPMs) in macular vessels in patients with BRVO/CRVO and in healthy controls using the Retinal Function Imager (RFI; Optical Imaging, Rehovot, Israel)...
October 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
Chun-Ju Lin, Huan-Sheng Chen, Cheng-Wen Su, Peng-Tai Tien, Jane-Ming Lin, Wen-Lu Chen, Chung-Yuan Kuo, Chun-Ting Lai, Yi-Yu Tsai
PURPOSE: To evaluate the effects of dexamethasone intravitreal implant (Ozurdex) and identify risk factors for repeated treatment in patients with macula edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). METHODS: Patients followed up for at least 6 months were enrolled from 2013 to 2016. Dexamethasone intravitreal implant was given as the baseline treatment. For evaluation of dexamethasone intravitreal implant effects and complications, the demographics, medical history, best-corrected visual acuity (BCVA), intraocular pressure, and central retinal thickness (CRT) were recorded...
September 26, 2017: Journal of Ocular Pharmacology and Therapeutics
Z Hladíková, E Klofáčová, B Kalvodová
PURPOSE: To evaluate 2-year follow-up results of patients with macular oedema (ME) caused by central (CRVO) and branch (BRVO) retinal vein occlusion treated with intravitreal ranibizumab at the Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. METHODS: Retrospective study. RESULTS: The 2-year follow-up was completed by 18 patients with ME caused by CRVO and 16 patients with ME caused by BRVO...
2017: Ceská a Slovenská Oftalmologie
Natalie Huang, W Andrew Lee, Sean Rivera, Sandra R Montezuma
PURPOSE: The aim of this report was to describe multimodal ocular imaging findings in a patient who presented with a ruptured retinal arterial macroaneurysm (RAM) associated with toxoplasmic Kyrieleis arteriolitis. METHODS: We report the case of a 64-year-old man with a history of systemic hypertension and dense amblyopia of the left eye who presented with decreased vision and new floaters in the left eye. Color fundus photography, spectral-domain optical coherence tomography, fluorescein angiography, and indocyanine green angiography were used as diagnostic imaging tools...
May 2017: Case Reports in Ophthalmology
Bora Yuksel, Omer Karti, Ozan Celik, Suleyman Gokhan Kerci, Tuncay Kusbeci
BACKGROUND: The aim was to make a real-world comparison of the efficacy of ranibizumab, dexamethasone and grid laser treatments in macular oedema due to branch retinal vein occlusion (BRVO). METHODS: Forty-four eyes of 44 consecutive patients with macular oedema secondary to BRVO were included. Treatment arms comprised standard care (StCARE, n = 15), intravitreal ranibizumab (RNB, n = 14) and dexamethasone implant (DEX, n = 15). No rescue laser was performed in DEX and RNB groups...
September 18, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"